Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

NCT05128487 is registered in ClinicalTrials.gov with Nimbus Saturn, Inc. as lead sponsor.

NCT NCT05128487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05128487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
Lead sponsor
Nimbus Saturn, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 5, 2021
Completion date
May 31, 2025
Enrollment
106 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

gastric and gastroesophageal junction (gej) adenocarcinoma, non-small cell lung cancer, renal cell carcinoma (kidney cancer), solid tumor